These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30928945)

  • 1. Treatment outcomes of initial differential antiretroviral regimens among HIV patients in Southwest China: comparison from an observational cohort study.
    Kang R; Luo L; Chen H; Zhu Q; Liao L; Xing H; Zhu J; Shen Z; Lan G; Tang Z; Shao Y; Yang W; Ruan Y
    BMJ Open; 2019 Mar; 9(3):e025666. PubMed ID: 30928945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment effects of the differential first-line antiretroviral regimens among HIV/HBV coinfected patients in southwest China: an observational study.
    Zhu J; Yang W; Feng Y; Lo C; Chen H; Zhu Q; Shen Z; Lan G; Chen Y; Tang Z; Xing H; Shao Y; Ruan Y; Li L
    Sci Rep; 2019 Jan; 9(1):1006. PubMed ID: 30700732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.
    Liu P; Liao L; Xu W; Yan J; Zuo Z; Leng X; Wang J; Kan W; You Y; Xing H; Ruan Y; Shao Y
    Medicine (Baltimore); 2018 Dec; 97(50):e13555. PubMed ID: 30558015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
    Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
    PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
    Asare K; Sookrajh Y; van der Molen J; Khubone T; Lewis L; Lessells RJ; Naidoo K; Sosibo P; van Heerden R; Garrett N; Dorward J
    Lancet Glob Health; 2024 Feb; 12(2):e282-e291. PubMed ID: 38142692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
    Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
    N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.
    Jouquet G; Bygrave H; Kranzer K; Ford N; Gadot L; Lee J; Hilderbrand K; Goemaere E; Vlahakis N; Trivino L; Makakole L; Cleary S
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):e68-74. PubMed ID: 21765366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Petlo C; Lockman S; Makhema J; Shapiro RL
    JAMA Pediatr; 2017 Oct; 171(10):e172222. PubMed ID: 28783807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
    Skhosana L; Steegen K; Bronze M; Lukhwareni A; Letsoalo E; Papathanasopoulos MA; Carmona SC; Stevens WS
    PLoS One; 2015; 10(2):e0118145. PubMed ID: 25659108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.
    Technau KG; Lazarus E; Kuhn L; Abrams EJ; Sorour G; Strehlau R; Reubenson G; Davies MA; Coovadia A
    Pediatr Infect Dis J; 2013 Aug; 32(8):851-5. PubMed ID: 23860481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
    Njuguna C; Orrell C; Kaplan R; Bekker LG; Wood R; Lawn SD
    PLoS One; 2013; 8(5):e63596. PubMed ID: 23717451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
    Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
    BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of adverse drug reaction among adult HIV-infected patients on antiretroviral therapy in government hospitals of Kaffa Zone, Ethiopia; November 2018: a retrospective cohort.
    Mitkie AA; Bekele FB; Debiso AT
    Pan Afr Med J; 2021; 38():181. PubMed ID: 33995787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.
    Han Y; Li Y; Xie J; Qiu Z; Li Y; Song X; Zhu T; Li T
    PLoS One; 2015; 10(3):e0120705. PubMed ID: 25821963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
    Cassim H; Otwombe K; Lazarus E; Liberty A; Gray GE; Greeff OBW; Violari A
    PLoS One; 2017; 12(7):e0180645. PubMed ID: 28686654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.